Leah N Klapper, PhD
Leah Klapper is Chief Technology Officer of FutuRx. Leah has been leading research and development in biotech start-ups for 20 years focusing on the advancement of academic programs from discovery to clinical proof of concept.
Before joining FutuRx, Leah served as CSO of Regenovation Ltd., a company developing acellular novel materials for in-situ tissue regeneration.
Previously, Leah served as CSO of BioLineRx Ltd., a biopharmaceutical development company focused on oncology, as General Manager of Bioline Innovations Jerusalem; an innovative biotechnology incubator and as Vice President of Research and Development at CureTech Ltd., a company that developed novel immune-modulating molecules.
Leah gained her post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle Washington in the fields of translational medicine and immune-therapeutics and holds a PhD in Immunology and Molecular Biology from the Weizmann Institute of Science in Rehovot Israel.